序号 |
标题 |
次数 |
作者 |
发布时间 |
67186 |
基因定点突变概念和应用 |
181 |
axc |
2024-12-12 |
67187 |
基因定点突变原理,详情介绍 |
266 |
axc |
2024-12-12 |
67188 |
基因点突变细胞株技术流程-CRISPR/Cas9技术 |
105 |
axc |
2024-12-12 |
67189 |
定点突变的目的及原理 |
203 |
axc |
2024-12-12 |
67190 |
基因定点突变技术 |
148 |
axc |
2024-12-12 |
67191 |
DOTA-JR-11,1039726-31-2,白色粉末状螯合剂 |
125 |
h |
2024-12-11 |
67192 |
DOTA-(Tyr3)-octreotate,204318-14-9,类似奥曲肽的多肽 |
95 |
h |
2024-12-11 |
67193 |
Edotreotide(DOTATOC),生长抑素类似物 |
111 |
h |
2024-12-11 |
67194 |
p-SCN-Bn-DOTA,127985-74-4,可用于标记多肽 |
109 |
h |
2024-12-11 |
67195 |
PAMAM-PEG-DOTA-Gd,聚酰胺-胺聚乙二醇DOTA钆 |
81 |
h |
2024-12-11 |
67196 |
螯合剂多肽,cyclo(RGDFK(DOTA)) |
115 |
h |
2024-12-11 |
67197 |
质粒构建的原理及方法 |
440 |
axc |
2024-12-11 |
67198 |
什么是基因过表达(gene overexpression) |
798 |
axc |
2024-12-11 |
67199 |
m-PEG6-(CH2)6-phosphonic acid,cas:2028284-71-9 |
91 |
zcy |
2024-12-11 |
67200 |
1201415-84-0,1180007-00-4,DOTA-Lys-Cys-COOH |
74 |
h |
2024-12-11 |
67201 |
CRISPR/Cas9系统基因敲除个别外显子(操作步骤) |
365 |
axc |
2024-12-11 |
67202 |
大环螯合物DOTA,DOTA-RGD |
69 |
h |
2024-12-11 |
67203 |
BocNH-O-(CH₂)₅-COOH BOC 保护基-氨基-五碳链-羧酸 |
116 |
zcy |
2024-12-11 |
67204 |
基因敲除方法,基因敲除小鼠定制服务 |
152 |
axc |
2024-12-11 |
67205 |
"Maleimide-(CH2)5-COONHS cas:55750-63-5 6-(马来酰亚胺基)己酸琥珀酰亚胺酯" |
87 |
zcy |
2024-12-11 |
67206 |
质粒构建的原理、步骤|质粒构建定制服务 |
372 |
axc |
2024-12-11 |
67207 |
DOTA-「Tyr3」-Octreotide,Edotreotide,奥曲肽的多肽 |
124 |
h |
2024-12-11 |
67208 |
Mal-PEG-CH2CO2H(马来酰亚胺) |
88 |
WYQ |
2024-12-11 |
67209 |
Stearic acid-PEG-CH2CO2H |
115 |
WYQ |
2024-12-11 |
67210 |
Dotatate,DOTA-奥曲肽 |
116 |
h |
2024-12-11 |
67211 |
螯合剂多肽DOTA-cyclo(RGDfK) |
99 |
h |
2024-12-11 |
67212 |
Biotin-PEG-CH2CO2H(生物素)(聚乙二醇)(甲基羧酸) |
138 |
WYQ |
2024-12-11 |
67213 |
Pomalidomide-PEG4-CH2COOH (CAS: 2097938-44-6) |
83 |
WYQ |
2024-12-11 |
67214 |
Pomalidomide-PEG2-CH2COOH (CAS: 2143097-05-4) |
86 |
WYQ |
2024-12-11 |
67215 |
Hydroxy-PEG1-CH2-Boc |
100 |
kx |
2024-12-11 |
67216 |
Thalidomide-O-PEG2-CH2-Ald (CAS: 2286368-58-7) |
126 |
WYQ |
2024-12-11 |
67217 |
双功能螯合剂DOTA-多肽;DOTA-cRGD 大环螯合剂修饰靶向环肽 |
96 |
h |
2024-12-11 |
67218 |
DSPE-PEG-CH2COOH(CAS: 474922-20-8) |
117 |
WYQ |
2024-12-11 |
67219 |
质粒构建的过程,制备方法 |
254 |
axc |
2024-12-11 |
67220 |
Tos-PEG1-CH2-Boc的应用和用途 |
115 |
kx |
2024-12-11 |
67221 |
204318-14-9,DOTA-(Tyr3)-octreotate,依多曲肽 |
67 |
h |
2024-12-11 |
67222 |
"Maleimide-(CH2)2-COOH cas:7423-55-4 3-马来酰亚胺基丙酸" |
141 |
zcy |
2024-12-11 |
67223 |
Propargyl-PEG3-CH2CO2H |
128 |
WYQ |
2024-12-11 |
67224 |
DOTA多肽分子探针,619300-53-7 |
103 |
h |
2024-12-11 |
67225 |
t-Boc-Aminooxy-PEG2-CH2CO2tBu(CAS: 2100306-57-6) |
75 |
WYQ |
2024-12-11 |
67226 |
β-NF-CH2-OH |
120 |
kx |
2024-12-11 |
67227 |
PEG5-(CH2CO2t-Butyl)2(CAS: 211746-78-0) |
113 |
WYQ |
2024-12-11 |
67228 |
Hydroxy-PEG4-CH2-Boc |
146 |
kx |
2024-12-11 |
67229 |
PEG6-(CH2CO2t-Butyl)2(CAS: 211746-79-1) |
119 |
WYQ |
2024-12-11 |
67230 |
七肽DOTA-YLYEIAR,1262403-91-7 |
102 |
h |
2024-12-11 |